Finance

Lists
ASMB:NASDAQ
Assembly Biosciences Inc
$22.53
+0.63%
(+0.14) 1D
Nov 19, 12:08:08 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ASMB...
Open
$22.36
High
$23.22
Low
$22.16
Mkt. cap
461.35M
Avg. vol.
259.96K
Volume
86.35K
52-wk high
$39.70
52-wk low
$19.20
EPS
-$0.37
Beta
1.26
Shares outstanding
20.48M
No. of employees
73
Open
$22.36
High
$23.22
Low
$22.16
Mkt. cap
461.35M
Avg. vol.
259.96K
Volume
86.35K
52-wk high
$39.70
52-wk low
$19.20
EPS
-$0.37
Beta
1.26
Shares outstanding
20.48M
No. of employees
73
News stories
From web sources and news partners
About Assembly Biosciences Inc
CEO-
Employees73
Founded2005
HeadquartersSouth San Francisco, California, United States
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 4 analysts giving stock ratings to ASMB in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for ASMB in the last 3 months.
Highest
Current $22.53
$53.00 (+135.24%)
Average
$48.50 (+115.27%)
Lowest
$43.00 (+90.86%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$50.00
+121.9%
11/17/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$43.00
+90.9%
11/16/2026
Ashwani Verma
UBS
Buy
Reiterated
$48.00
+113%
11/03/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$53.00
+135.2%
08/31/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$43.00
+90.9%
08/16/2026
Unknown Analyst
Mizuho Securities
Buy
Maintained
$45.00
+99.7%
06/12/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
-$0.93 / -$0.49
-87.98%miss
Revenue / Est. (USD)
2.96M / 7.26M
-59.28%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
42.47M
8.21M
13.37M
2.96M
Cost of goods sold
17.25M
14.90M
14.92M
20.23M
Cost of revenue
17.25M
14.90M
14.92M
20.23M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.42M
4.68M
4.80M
6.14M
Operating expense
5.42M
4.68M
4.80M
6.14M
Total operating expenses
22.67M
19.58M
19.72M
26.37M
Operating income
19.80M
-11.37M
-6.34M
-23.42M
Other non operating income
-
-
-
-
EBT including unusual items
22.09M
-9.08M
-3.86M
-20.26M
EBT excluding unusual items
22.09M
-9.08M
-3.86M
-20.26M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
22.09M
-9.08M
-3.86M
-20.26M
Net profit margin
52.01%
-110.54%
-28.84%
-685.25%
Earnings per share
2.48
-0.54
-0.20
-0.93
Interest and investment income
2.29M
2.29M
2.49M
3.16M
Interest expense
-
-
-
-
Net interest expenses
2.29M
2.29M
2.49M
3.16M
Depreciation and amortization charges
-
-
-
-
EBITDA
19.83M
-11.34M
-6.32M
-23.39M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps